Form 8-K - Current report:
SEC Accession No. 0001193125-25-261663
Filing Date
2025-11-03
Accepted
2025-11-03 07:10:08
Documents
11
Period of Report
2025-11-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kpti-20251103.htm   iXBRL 8-K 72619
2 EX-99.1 kpti-ex99_1.htm EX-99.1 307250
  Complete submission text file 0001193125-25-261663.txt   518649

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kpti-20251103.xsd EX-101.SCH 30858
13 EXTRACTED XBRL INSTANCE DOCUMENT kpti-20251103_htm.xml XML 4700
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 251442092
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)